Harrow, Inc. (NASDAQ:HROW) Shares Bought by Westside Investment Management Inc.

Westside Investment Management Inc. increased its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 6.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 173,856 shares of the company's stock after purchasing an additional 10,315 shares during the quarter. Harrow accounts for 1.0% of Westside Investment Management Inc.'s holdings, making the stock its 22nd biggest position. Westside Investment Management Inc. owned about 0.49% of Harrow worth $4,625,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new position in Harrow during the 4th quarter worth approximately $25,000. Tower Research Capital LLC TRC raised its position in Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after buying an additional 1,462 shares during the period. Aquatic Capital Management LLC purchased a new stake in Harrow in the 4th quarter worth about $78,000. AlphaQuest LLC boosted its position in Harrow by 452.8% during the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after acquiring an additional 2,889 shares during the period. Finally, GAMMA Investing LLC grew its stake in Harrow by 2,401.2% during the 1st quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock valued at $1,670,000 after acquiring an additional 6,027 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. BTIG Research began coverage on shares of Harrow in a research report on Thursday, June 12th. They set a "buy" rating and a $62.00 price objective on the stock. B. Riley cut their price target on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. William Blair began coverage on Harrow in a report on Tuesday, June 10th. They issued an "outperform" rating on the stock. Finally, HC Wainwright boosted their target price on shares of Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $61.40.

Harrow Stock Performance

Shares of HROW opened at $30.88 on Monday. The company has a market capitalization of $1.13 billion, a PE ratio of -55.14 and a beta of 0.40. The company has a debt-to-equity ratio of 2.01, a current ratio of 0.91 and a quick ratio of 0.85. Harrow, Inc. has a one year low of $20.36 and a one year high of $59.23. The company's fifty day moving average price is $27.62 and its 200 day moving average price is $28.96.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). The business had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative net margin of 10.19% and a negative return on equity of 25.01%. As a group, analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current year.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.